Katrin Sproesser
YOU?
Author Swipe
View article: Supplemental Materials and Methods and Figure Legends from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma
Supplemental Materials and Methods and Figure Legends from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma Open
Supplemental Materials and Methods and Figure Legends from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma
View article: Supplemental Figure S2 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma
Supplemental Figure S2 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma Open
Figure S2. Combinatorial inhibition of RRM2 and mutant BRAF increases DNA damage accumulation and apoptosis, which correlates with decreased expression of DNA damage repair genes.
View article: Supplemental Table 1 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma
Supplemental Table 1 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma Open
Supplemental Table 1
View article: Supplemental Figure S3 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma
Supplemental Figure S3 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma Open
Figure S3. Knockdown of RRM2 prolongs PLX4720 treatment response after drug withdrawal.
View article: Supplemental Figure S1 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma
Supplemental Figure S1 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma Open
Figure S1. Combinatorial inhibition of RRM2 and mutant BRAF inhibits cell proliferation to a greater extent than either treatment alone.
View article: Supplemental Figure S4 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma
Supplemental Figure S4 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma Open
Figure S4. The combination of knockdown of RRM2 and mutant BRAF inhibition in a patient derived xenograft inhibits melanoma tumor growth.
View article: Supplemental Figure S2 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma
Supplemental Figure S2 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma Open
Figure S2. Combinatorial inhibition of RRM2 and mutant BRAF increases DNA damage accumulation and apoptosis, which correlates with decreased expression of DNA damage repair genes.
View article: Data from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma
Data from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma Open
The majority of patients with melanoma harbor mutations in the BRAF oncogene, thus making it a clinically relevant target. However, response to mutant BRAF inhibitors (BRAFi) is relatively short-lived with progression-free survival of only…
View article: Supplemental Table 1 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma
Supplemental Table 1 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma Open
Supplemental Table 1
View article: Supplemental Materials and Methods and Figure Legends from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma
Supplemental Materials and Methods and Figure Legends from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma Open
Supplemental Materials and Methods and Figure Legends from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma
View article: Supplemental Figure S1 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma
Supplemental Figure S1 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma Open
Figure S1. Combinatorial inhibition of RRM2 and mutant BRAF inhibits cell proliferation to a greater extent than either treatment alone.
View article: Supplemental Figure S3 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma
Supplemental Figure S3 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma Open
Figure S3. Knockdown of RRM2 prolongs PLX4720 treatment response after drug withdrawal.
View article: Data from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma
Data from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma Open
The majority of patients with melanoma harbor mutations in the BRAF oncogene, thus making it a clinically relevant target. However, response to mutant BRAF inhibitors (BRAFi) is relatively short-lived with progression-free survival of only…
View article: Supplemental Figure S4 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma
Supplemental Figure S4 from Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma Open
Figure S4. The combination of knockdown of RRM2 and mutant BRAF inhibition in a patient derived xenograft inhibits melanoma tumor growth.
View article: Table S5 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance
Table S5 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance Open
Supplementary Table
View article: Table S3 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance
Table S3 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance Open
Supplementary Table
View article: Table S1 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance
Table S1 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance Open
Supplementary Table
View article: Table S2 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance
Table S2 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance Open
Supplementary Table
View article: Supplementary Figures from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance
Supplementary Figures from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance Open
Supplementary Figures
View article: Table S4 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance
Table S4 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance Open
Supplementary Table
View article: Table S4 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance
Table S4 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance Open
Supplementary Table
View article: Data from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance
Data from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance Open
Metastatic melanoma is challenging to clinically address. Although standard-of-care targeted therapy has high response rates in patients with BRAF-mutant melanoma, therapy relapse occurs in most cases. Intrinsically resistant melanoma cell…
View article: Table S1 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance
Table S1 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance Open
Supplementary Table
View article: Table S2 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance
Table S2 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance Open
Supplementary Table
View article: Data from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance
Data from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance Open
Metastatic melanoma is challenging to clinically address. Although standard-of-care targeted therapy has high response rates in patients with BRAF-mutant melanoma, therapy relapse occurs in most cases. Intrinsically resistant melanoma cell…
View article: Table S3 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance
Table S3 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance Open
Supplementary Table
View article: Supplementary Figures from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance
Supplementary Figures from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance Open
Supplementary Figures
View article: Table S5 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance
Table S5 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance Open
Supplementary Table
View article: Supplementary Figure S1 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies
Supplementary Figure S1 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies Open
All growth curves of first implantation and subsequent expansions with and without continuous BRAF inhibitor (PLX4720) diet. Error bars are SEM.
View article: Movie S5 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Movie S5 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma Open
Time-lapse imaging of A375(Fucci2)-CR cells treated with the control.